Author

Stefan Fruehauf

Observed names: S. Fruehauf, Stefan Fruehauf???

Institution: Klinik Dr. Hancken

Observed institutions: Heidelberg University, Klinik Dr. Hancken

ORCID: 0000-0002-4909-7427

Observed ORCID: 0000-0002-4909-7427

OpenAlex ID: A5084437489

Neurobehavioral toxicity of total body irradiation: a follow-up in long-term survivors

2000 · Martin Peper, Sarah Steinvorth, et al. · International Journal of Radiation Oncology*Biology*Physics · 60

Favorable therapeutic index of a p210 BCR-ABL -specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

1999 · Bernd Kasper, Stefan Fruehauf, et al. · Cancer Chemotherapy and Pharmacology · 42

Sustained Remission of Idiopathic Hypereosinophilic Syndrome following α-lnterferon Therapy

2009 · Stefan Fruehauf, Christoph Fiehn, et al. · Acta Haematologica · 23

Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)

2024 · Arndt Stahler, Andreas J. Kind, et al. · Clinical Cancer Research · 21

PDF

Differential expression of a recombinant adeno-associated virus 2 vector in human CD34+ cells and breast cancer cells

2000 · Marlon R Veldwijk, Stefan Fruehauf, et al. · Cancer Gene Therapy · 19

Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)

2023 · Arndt Stahler, Beeke Hoppe, et al. · Journal of Clinical Oncology · 17

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)

2023 · K. Heinrich, M. Karthaus, et al. · ESMO Open · 14

PDF

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer

2022 · G. Sommerhäuser, A. Kurreck, et al. · BMC Cancer · 9

PDF

Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212)

2022 · Greta Sommerhäuser, Annika Kurreck, et al. · European Journal of Cancer · 8

Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial

2025 · Alexej Ballhausen, Susanna Swoboda, et al. · Clinical Cancer Research · 7

Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial

2024 · Arndt Stahler, Meinolf Karthaus, et al. · EClinicalMedicine · 6

Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer

2025 · Arndt Stahler, Dominik Paul Modest, et al. · Journal of Clinical Oncology · 4

Graduated Systemic Treatment of AIDS-Associated Kaposi Sarcoma: In the Era of Highly Active Antiretroviral Therapy

2004 · Ulrich R Hengge, Gudrun Tossing, et al. · American Journal of Cancer · 4

Negative hyperselection for mutations associated with anti-EGFR antibody resistance in RAS wildtype metastatic colorectal cancer (mCRC): Evaluation of the PANAMA trial (AIO-KRK-0212, maintenance therapy with 5-FU, folinic acid (FU/FA) with or without panitumumab).

2022 · Andreas Jay Kind, Dominik Paul Modest, et al. · Journal of Clinical Oncology · 3

Deep Learning–Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer

2026 · Julius Keyl, René Hosch, et al. · Clinical Cancer Research · 2

FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses.

2024 · Dominik Paul Modest, Meinolf Karthaus, et al. · Journal of Clinical Oncology · 1

PDF

Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of RAS wild-type (WT) metastatic colorectal cancer (mCRC): Pooled analysis of the randomized trials FIRE-1, FIRE-3, XELAVIRI, and PanaMa.

2024 · Arndt Stahler, Dominik Paul Modest, et al. · Journal of Clinical Oncology · 1

PDF

Combined amphiregulin and epiregulin expression as a prognostic and predictive biomarker of panitumumab (Pmab), fluorouracil, and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab+FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212).

2024 · Arndt Stahler, Beeke Hoppe, et al. · Journal of Clinical Oncology · 1

Supplementary Data 1 from Deep Learning–Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer

2026 · Julius Keyl, René Hosch, et al.

Data from Deep Learning–Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer

2026 · Julius Keyl, René Hosch, et al.

Supplementary Table S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial